Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncotelic TherapeuticsOTLC +0.73% 3-1 Month Momentum % is 17.38% as of Aug. 01, 2026. The stock has 4 warning signs investors should review. Among 1,389 Biotechnology companies, Oncotelic Therapeutics ranks better than 82% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-01), Oncotelic Therapeutics's 3-1 Month Momentum % is 17.38%.
The industry rank for Oncotelic Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
OTLC's 3-1 Month Momentum % is ranked better than 82% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs OTLC: 17.38
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Oncotelic Therapeutics 3-1 Month Momentum % Related Terms
OTLC vs KTTA, LSTA, CYCN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Oncotelic Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics (OTLC) has a 3-1 Month Momentum % of 17.38% as of Aug. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oncotelic Therapeutics and its competitors. According to the industry distribution chart, Oncotelic Therapeutics ranks #250 out of 1389 companies in the Biotechnology industry, placing it in the top 18%.
Is Oncotelic Therapeutics' 3-1 Month Momentum % too high?
Oncotelic Therapeutics' current 3-1 Month Momentum % is 17.38%. Based on the distribution chart, Oncotelic Therapeutics ranks #250 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Oncotelic Therapeutics' 3-1 Month Momentum % compare to KTTA and LSTA?
According to the Biotechnology industry distribution chart, Oncotelic Therapeutics ranks #250 out of 1389 companies for 3-1 Month Momentum %. This places Oncotelic Therapeutics in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oncotelic Therapeutics and its competitors. Oncotelic Therapeutics's current 3-1 Month Momentum % is 17.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current 3-1 Month Momentum % of 17.38%. The current 3-1 Month Momentum % is 17.38%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current 3-1 Month Momentum % is 17.38% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLC has been successfully added to your 
